“…Examples involve a recombinant, protein A-and IsdB-N2-containing five-antigen S. aureus vaccine (rFSAV) as well as SA4Ag, a multicomponent vaccine composed of capsular polysaccharide conjugates and recombinant forms of ClfA and the staphylococcal manganese transporter C (MntC; Creech et al, 2017 ; Frenck et al, 2017 ; Zeng et al, 2020 ). However, various clinical trials ended in failure due to adverse effects or limited efficacy in diseased patients ( Clegg et al, 2021 ), thereby asking for improved vaccination strategies that may encompass probiotic-based immunization ( Pan et al, 2023 ), advanced antibody engineering ( Chen et al, 2020 , 2022 ), or usage of live-attenuated vaccine platforms ( Cabral et al, 2017 ; Moscoso et al, 2018 ). Alternatively, chemical interference with the transpeptidase activity of sortase A may also help to limit S. aureus colonization and severity of staphylococcal disease.…”